# Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?

> **NCT01481883** · PHASE4 · COMPLETED · sponsor: **The Alfred** · enrollment: 13 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder
- Schizophreniform Disorder

## Interventions

- **DRUG:** Raloxifene Hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01481883
- **Lead sponsor:** The Alfred
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2019-01
- **Final completion:** 2019-02
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01481883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01481883, "Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT01481883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*